Suppr超能文献

电针减少非酒精性脂肪性肝炎患者MRI-PDFF上的脂肪变性:一项随机对照试验性临床试验

Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: a randomized controlled pilot clinical trial.

作者信息

Zhao Jingjie, Wang Qianyi, Zhao Xinyu, Wu Lina, Li Juanjuan, Zhang Wen, Xu Shuai, Han Chaoru, Du Yi, Tong Xiaofei, Duan Weijia, Cao Di, Ren Hao, Zhao Xinyan, Ou Xiaojuan, Jia Jidong, You Hong

机构信息

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center of Digestive Diseases, No. 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.

Clinical Center for Metabolic Associated Fatty Liver Disease, Capital Medical University, Beijing, China.

出版信息

Chin Med. 2023 Feb 24;18(1):19. doi: 10.1186/s13020-023-00724-w.

Abstract

BACKGROUND

Non-alcoholic steatohepatitis (NASH) had not yet been approved therapy. Electro-acupuncture (EA) has been reported to have potential efficacy. However, high-quality clinical evidence was still lacking.

METHODS

NASH patients were randomized and allocated to either sham acupuncture (SA) or EA group in a 1:1 ratio, with the patient blinded. Each patient received 36 sessions of SA or EA treatment over 12 weeks, followed by additional 4 weeks. The primary outcome was the changes in relative liver fat content measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF).

RESULTS

A total of 60 patients were enrolled. From baseline to week 12, the reduction of relative liver fat content measured by MRI-PDFF in the EA group (- 33.6%, quantile range: - 52.9%, - 22.7%) was significantly more significant than that in the SA group (- 15.8%, quantile range: - 36.1%, - 2.7%) (p = 0.022). Furthermore, the EA group had more patients who achieved MRI-PDFF to 30% reduction at week 12 (53.3% vs. 25.9%, p = 0.035). EA treatment also significantly reduced body weight (- 3.0 vs. + 0.1 kg, p = 0.034) and BMI (- 1.5 vs. - 0.2 kg/m, p = 0.013) at week 16. Except for AST (- 27.4 vs. - 16.2 U/L, p = 0.015), other biochemical varieties, including ALT, fasting-glucose, cholesterol, and triglyceride, showed no statistically significant difference. Both groups measured no significant changes in liver stiffness by magnetic resonance elastography (MRE). There were no serious adverse events in either group.

CONCLUSIONS

Twelve weeks of EA effectively and safely reduces relative liver fat content in NASH patients. Further multicenter randomized controlled studies are needed. Trial registration Chinese Clinical Trial Registry, ChiCTR2100046617. Registered 23 May 2021, http://www.chictr.org.cn/edit.aspx?pid=127023&htm=4.

摘要

背景

非酒精性脂肪性肝炎(NASH)尚无获批的治疗方法。据报道,电针(EA)可能具有疗效。然而,仍缺乏高质量的临床证据。

方法

将NASH患者按1:1比例随机分配至假针刺(SA)组或EA组,患者处于盲态。每位患者在12周内接受36次SA或EA治疗,随后再进行4周治疗。主要结局是通过磁共振成像质子密度脂肪分数(MRI-PDFF)测量的相对肝脏脂肪含量的变化。

结果

共纳入60例患者。从基线到第12周,EA组通过MRI-PDFF测量的相对肝脏脂肪含量的降低幅度(-33.6%,四分位数范围:-52.9%,-22.7%)显著大于SA组(-15.8%,四分位数范围:-36.1%,-2.7%)(p = 0.022)。此外,在第12周时,EA组有更多患者实现MRI-PDFF降低30%(53.3%对25.9%,p = 0.035)。在第16周时,EA治疗还显著降低了体重(-3.0对+0.1 kg,p = 0.034)和BMI(-1.5对-0.2 kg/m²,p = 0.013)。除了谷草转氨酶(AST)(-27.4对-16.2 U/L,p = 0.015)外,其他生化指标,包括谷丙转氨酶、空腹血糖、胆固醇和甘油三酯,均无统计学显著差异。两组通过磁共振弹性成像(MRE)测量的肝脏硬度均无显著变化。两组均未出现严重不良事件。

结论

12周的EA治疗可有效且安全地降低NASH患者的相对肝脏脂肪含量。需要进一步开展多中心随机对照研究。试验注册 中国临床试验注册中心,ChiCTR2100046617。于2021年5月23日注册,http://www.chictr.org.cn/edit.aspx?pid=127023&htm=4。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f37/9951510/fd501f2c789a/13020_2023_724_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验